[Anti-TNF-alpha-treatment of arthritis--4-year follow-up].
Petri
Anne
A
Parker Instituttet, Reumatologisk Klinik, Medicinsk Center, H:S Frederiksberg Hospital, DK-2000 Frederiksberg. hb@fh.hosp.dk
Dreyer
Lene
L
Danneskiold-Samsøe
Bente
B
Terslev
Lene
L
Bliddal
Henning
H
D000328:Adult; D000368:Aged; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D011993:Recombinant Fusion Proteins; D000068800:Etanercept